pharmaceutical investing Sorrento and Celularity to Start Anti-CD38 CAR-T Phase 1 Clinical Trial in Patients With Relapsed or Refractory Multiple Myeloma
E-Power Resources Inc. Announces Closing of Oversubscribed Hard Dollar and Flow-through Private Placements